Regeneron price target raised to $1,057 from $850 at Canaccord

Canaccord raised the firm’s price target on Regeneron (REGN) to $1,057 from $850 and keeps a Buy rating on the shares. The firm said they expect Dupixent growth to continue to outpace EYLEA revenues, providing upside going forward. Sanofi collaboration revenue surpassed US EYLEA revenues for the first time in 1Q25, and the gap should continue to widen. As EYLEA sales continue to decline, they see Dupixent as the key growth driver going forward.